See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Tariffs
Natural Disasters
Trade War
Donald Trump
Social Media
Baseball
Stock Markets
Artificial Intelligence
Education
Soccer
Trade
Property
Published • loading... • Updated

Baseline Analysis of MINDFuL Trial Highlights Screening Success of Enrolling Patients With Immune Dysfunction

Summary by neurologylive.com
Data suggests that immune dysfunction biomarkers do not pose a major barrier to patient enrollment in Alzheimer’s research, as most patients meeting general AD criteria also qualified under immune dysfunction criteria.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
neurologylive.comneurologylive.com

Baseline Analysis of MINDFuL Trial Highlights Screening Success of Enrolling Patients With Immune Dysfunction

Data suggests that immune dysfunction biomarkers do not pose a major barrier to patient enrollment in Alzheimer’s research, as most patients meeting general AD criteria also qualified under immune dysfunction criteria.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

neurologylive.com broke the news in on Friday, April 4, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Alzheimer's Disease

Alzheimer's Disease

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal